Bioceltix S.A. (FRA:XI3)

Market Cap	79.06M -30.1%
Revenue (ttm)	n/a
Net Income	-4.31M
EPS	-0.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	20.40
Previous Close	20.40
Day's Range	20.40 - 20.40
52-Week Range	13.98 - 28.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Bioceltix

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company’s products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 49
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XI3

Financial Performance

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error